

Figure 1


Ave NL.
300
250
200
150
100
50
0
GST alone
GST-Nogo5&6
1 in 4
1 in 8
1in 16
1 in 32

Figure 2


Ave. NL
250
200
150
100
50
0
GST alone
GST-Nogo 5&6
1 in 4
1 in 8
1 in 16
1 in 32

Figure 3


Ave NL
300
250
200
150
100
50
0
GST alone
GST-Nogo 5&6
1 in 4
1 in 8
1 in 16
1 in 32

Figure 4


Mean Neurite Length
0
20
40
60
80
100
120
140
160
180
GSTalone
GSTNgA5+6
Neat
1 in 2
1 in 4
1 in 8

Figure 5


Average Neurite Length/Neurite
900
800
700
600
500
400
300
200
100
0
GST
Nogo5+6
8ug/ml
4ug/ml
2ug/ml
1ug/ml

Figure 6


Ave NL
250
200
150
100
50
0
GST
GST-Nogo5&6
500ug/ml
250ug/ml
125ug/ml
62.5ug/ml

Figure 7



Figure 8



Figure 9


Control (n=13)
5 ug (n=12)
15 ug (n=7, overall P<0.01 vs control, repeated measures analysis)
Neurological Score
Time (Days)
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
0
10
20
30
40
50
60
* P < 0.05 vs control, data represented as means +/- SEM

Figure 10


Control (n=13)
15 ug (n=7)
5ug (n=12)
Paw Placements
17.5
15.0
12.5
10.0
7.5
5.0
2.5
0.0
0
10
20
30
40
50
60
Time (days)

Figure 11A


Control (n=13)
15 ug (n = 7)
5 ug (n= 12)
Paw Placements
10.0
7.5
5.0
2.5
0.0
0
10
20
30
40
50
60
Time (days)

Figure 11B



Figure 11C

13/45


Control n=13
1 dose less n=3
full dose n=4, ** P< 0.01
overall in comparison to control
Paw Placements
Time (days)
0
1
2
3
4
5
6
7
8
0
10
20
30
40
50
60

Figure 11D



Figure 12



Figure 13


Control (n=13)
5 ug (n= 12)
15 ug (n=7)
Body Weight (g)
600
550
500
450
400
350
300
250
200
Time (Days)
0
10
20
30
40
50
60
* P<0.05 vs control, repeated measures analysis

Figure 14A


Dosing 3
Dosing 4
Weight (g)
600
550
500
450
400
350
300
250
200
1h
24h
1wk
2wk
3wk
4wk
5wk
6wk
7wk
8wk
TIME

Figure 14B


Control
5ug
15 ug dosed 3 times
15 ug dosed 4 times
Bodyweight (g)
600
550
500
450
400
350
300
250
1H
24H
7D
14D
21D
28D
35D
42D
49D
59D
TIME

Figure 14C


2C4 3mg/kg
2A10 3mg/kg
Control
2A10 10mg/kg
Average % Lesion Volume
0
5
10
15
20
25
30
35
40
45
50
Dose groups

Figure 15


2C4 4.7 mg/kg
2A10 3mg/kg
Control IgG2A
2 A10 10 mg/kg
Neuroscore
30
25
20
15
10
5
0
0
7
14
21
28
35
42
49
56
Time (days)
* P<0.05 2A10 10 mg/kg vs Control Group

Figure 16


2C4 (4.7mg/kg)
2A10 (3mg/kg)
IgG2a (3mg/kg)
2A10 (10mg/kg)
Paw placements
17.5
15.0
12.5
10.0
7.5
5.0
2.5
0.0
0
7
14
21
28
35
42
49
56
Time (days)

Figure 17A


2C4 (4.7mg/kg)
2A10 (3mg/kg)
IgG2a (3mg/kg)
2A10 (10mg/kg)
Paw placements
10.0
7.5
5.0
2.5
0.0
Time (days)
0
7
14
21
28
35
42
49
56
*
*
*
*
**

Figure 17B


2C4 (4.7mg/kg)
2A10 (3mg/kg)
IgG2a (3mg/kg)
2A10 (10mg/kg)
Paw placements
Time (Days)
0
1
2
3
4
0
7
14
21
28
35
42
49
56
*
**

Figure 17C


2C4 3mg/kg
2A10 3mg/kg
Control IgG2a 3mg/kg
2A10 10mg/kg
Total footslips
0
2
4
6
8
10
12
14
16
18
Baseline
Week1
Week2
Week3
Week4
Week5
Week6
Week7
Week8
Post MCAo

Figure 18


2C4 3mg/kg
2A10 3mg/kg
Contol IgG2a 3mg/kg
2A10 10mg/kg
Total footslips
0
2
4
6
8
10
12
14
16
18
Baseline
Week1
Week2
Week3
Week4
Week5
Week6
Week7
Week8
Post McAo

Figure 19


2C4 3mg/kg
2A10 3mg/kg
Control IgG2a 3mg/kg
2A10 10mg/kg
Mean latency (secs)
50
40
30
20
10
0
-1
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6
Week 7
Week 8
Weeks post MCAo

Figure 20


Secreted Abeta40
3500
3000
2500
2000
1500
1000
500
0
Vector
GFP
Nogo-A-flag
Nogo-B-myc
Nogo-C-myc

Figure 21


Secreted ABeta42/mg
12000
10000
8000
6000
4000
2000
0
Vector
GFP
Nogo-A-flag
Nogo-B-myc
Nogo-C-myc

Figure 22


Abeta40 UNITS
25000
20000
15000
10000
5000
0
PCDNA3
NOGO-A FLAG

Figure 23


Abeta42
1800
1600
1400
1200
1000
800
600
400
200
0
PCDNA3
NOGO-A FLAG

Figure 24


Abeta40
Abeta42
Normalised to Vector Transfected Cells
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
Vector
GFP
Nogo-Aflag
NogoBmyc
NogoCmyc

Figure 25


Ab40
Ab42
% inhibition
100
90
80
70
60
50
40
30
20
10
0
Concentration of antibody (ug/ml)
30
10
3
1
0

Figure 26


Abeta 40
Abeta 42
% inhibition
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
0
100
50
30
25
20
15
10
5
3
1
0
Concentration of antibody ug/ml

Figure 27


Abeta 40
Abeta 42
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
% inhibition
0
100
50
30
25
20
15
10
5
3
1
0
Concentration of antibody ug/ml

Figure 28


Abeta 40
Abeta 42
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
% inhibition
0
100
50
30
25
20
15
10
5
3
1
0
Concentration of antibody ug/ml

Figure 29


Abeta 40
Abeta 42
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
% inhibition
0
100
50
30
25
20
15
10
5
3
1
0
Concentration of antibody ug/ml

Figure 30


Abeta 40
Abeta 42
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
% inhibition
0
50
30
25
20
15
10
5
3
1
0.3
0
Concentration of antibody ug/ml

Figure 31


Abeta 40
Abeta 42
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
% inhibition
0
50
30
25
20
15
10
5
3
1
0.3
0
Concentration of antibody ug/ml

Figure 32


Ab40
Ab42
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
% inhibition
20
10
3
1
0.3
0
Concentration of antibody ug/ml

Figure 33


Abeta 40
Abeta 42
% Inhibition
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
PBS
2A10: 10ug/ml
2C4: 18ug/ml
15C3: 99ug/ml
10A4:50ug/ml
10A4:25ug/ml
IgG2b: 30ug/ml
IgG2b: 10ug/ml
14D12. 1E6:30ug/ml
14D12. 1E6:10ug/ml
50% PBS
PBS
Antibody/Concentration ug/ml

Figure 34


Binding to human Nogo
HcLc
H1L11
OD 490 nm
0
1
2
3
4
0.0001
0.001
0.01
0.1
1
10
[2A10] ug/ml

Figure 35A



Figure 35B



Figure 35C


NogoAmyc (μg):
0
1
1.5
2
3
4
5
% increase of Aβ40
100.00
80.00
60.00
40.00
20.00
0.00
vector
NgA (1ug)
NgA (1.5ug)
NgA (2ug)
NgA (3ug)
NgA (4ug)
NgA (5ug)

Figure 36